By Christina Alfonso, Executive Director, Council on Global Competition and Innovation – CGCI, and Zachary Yerushalmi, Co-Founder and CEO, Elevate Quantum
When Neil Armstrong planted the U.S. flag on the moon in 1969, it marked more than just a Cold War milestone—it was the triumphant climax of an era defined by science, ambition, and state-backed technological investment. The Space Race was much more than a symbolic victory—it was underpinned by a host of revolutionary technology advances: semiconductors, computers, telecommunications, and advanced materials that came to forge our contemporary civilization.
Today, we stand at the threshold of a transformation just as profound. But this time, the frontier isn’t space—it’s quantum. For investors, this technology revolution could similarly prove as compelling as any that came before…if you play it smart.
Quantum computing is a specific application of quantum principles. It is more than a ‘better’ computer—it fundamentally reimagines what a computer is. Classical machines, from ancient counting boards to modern supercomputers, operate through binary logic and sequential processing, methodically working through calculations one operation after another. Quantum computers, by contrast, exploit the probabilistic nature of quantum physics to navigate every possible solution simultaneously. This radical departure enables quantum systems to crack problems at speeds that would leave even our most powerful classical computers hopelessly behind.
The implications are staggering. Quantum computing’s revolutionary capabilities promise to reshape virtually every sector of human endeavor. Even setting aside the existential threat to modern cryptography—where quantum algorithms could shatter most of today’s key encryption standards—you’d be hard-pressed to find a clearer path to modeling and manipulating the atomic building blocks of the physical world.[1] From accelerating drug discovery and novel antivirals to unlocking energy-dense materials and grid-scale storage, quantum computers offer a shot at realizing a touch of the Jetsons in our own time. These new computers are estimated to unlock $3.5 trillion in value, somewhere on the scale of the life sciences and financial services sectors in our economy.
This transformation is no longer theoretical. As global powers race to harness quantum capabilities, the stakes extend beyond commercial opportunity to national security imperatives. Falling behind in quantum technology risks ceding strategic advantage to adversaries, making responsible investment not just prudent but essential for maintaining technological leadership and safeguarding our future.
With humanity on the cusp of our science-fiction future, the key question for sophisticated investors is how to support this industry and allocate capital toward this critical emerging technology—one recognized by organizations like the Council on Global Competition and Innovation (CGCI) as a pillar of future competitiveness—without falling victim to its hype cycle.
The ‘newness’ of the quantum industry makes the question hard to answer. Venture models built around software overlook the ‘physical’ reality and stage of the industry. Qubits – the building blocks of these quantum systems – are exquisite and still hamstrung by technical challenges before they can achieve full commercial scale. The semiconductor investment playbook is closer to quantum’s hardware roots. But semiconductors benefit from mature markets and decades of implementation experience. Quantum, by contrast, hasn’t settled on any commercially tractable architecture yet, with many nascent approaches—trapped-ion, photonics, superconductors—all still years from commercial scale. That maturity gap means both software and semiconductor analogues are the wrong frameworks for quantum investment right now.
Given these realities, investors looking for a more fitting roadmap might consider the biotech sector. Like quantum, biotech is defined by technical complexity, long development timelines, and the need for patient, diversified investment.
Applying the Biotech Playbook to Quantum Investing
Successful biotech investment strategies typically share three features:
- Portfolio construction. Smart investors usually avoid “betting the farm” on one exciting preclinical drug still five to ten years away from definitive trial results. Instead, they build a portfolio across modalities—small molecules, biologics, gene therapies—and across disease areas to balance risk and increase the chance of success on a portfolio basis.
- Alignment with payers and regulators. In biotech, programs like the Orphan Drug Act created incentives—market exclusivity, tax credits, reduced fees—for rare-disease therapies. Smart investors align closely to these regulatory programs to drive top returns.
- Mastery takes time. There’s no such thing as an effective crash course on biotech investing—it’s a game played by seasoned hands. It takes decades to develop the technical and commercial expertise needed to distinguish transformative platforms from hype.
Taken together, these lessons from biotech offer a more realistic and resilient framework for quantum investing. Instead of chasing a single moonshot, investors should build diversified portfolios across multiple hardware approaches and layers of the value chain—from enabling technologies like cryogenics and control systems to systems integrators and application developers. The goal isn’t to predict a lone winner but to position across the ecosystem where progress is likely to compound.
Equally important is aligning investments with customers willing to pay, including government agencies and global corporations that view quantum as a strategic asset. And just like biotech, quantum demands domain fluency and long-term orientation: success won’t come from generalist venture models alone, but from investors teamed with seasoned technologists and operational experts who understand the steep path to commercialization.
The upside, however, is immense—and already taking shape. Consider Lightsynq—a Harvard- and AWS-backed spinout acquired by IonQ for more than $400 million in stock just six months after its founding. Or Oxford Ionics, a UK company bought for $1.08 billion in a cash-and-stock deal that expanded and accelerated IonQ’s technology roadmap. These exits show that when companies deliver foundational technology advancement the market doesn’t wait for full commercial scale to reward progress.
Chasing returns, private and public capital is flowing fast. The Chinese government plans to invest over $15 billion in quantum technologies in the coming years. The U.S. strategy leverages public and private capital alongside regional initiatives like Elevate Quantum—a consortium of public and private players across the Mountain West working to accelerate commercialization and secure national leadership. Quantum’s potential is precisely why it remains one of eight priority technologies identified by the Council on Global Competition and Innovation (CGCI).
Quantum computing won’t follow traditional venture maps. It’s hardware-led, talent-intensive, and years from broad adoption. But that doesn’t mean it’s too early—it just means it requires the right lens: patient capital, technical credibility, diversified bets, and the humility not to treat today’s front-runners as final winners. If quantum lives up to even a fraction of its potential, it could reshape trillion-dollar sectors. But realizing that future—and earning a return along the way—demands more than optimism. It requires strategy, staying power, and an investor mindset sharp enough to spot signal through the quantum noise.
About the Authors
Christina Alfonso is the Executive Director of the Council on Global Competition and Innovation – CGCI.
Zachary Yerushalmi is the Co-Founder and CEO of Elevate Quantum—the first and only major place‑based investment the U.S. government has made in the quantum industry. Elevate Quantum is a federally recognized consortium backed by 140+ organizations, including Microsoft, AWS, Google, Sandia National Labs, Quantinuum, Atom Computing, Infleqtion, and more, working to accelerate commercialization and cement U.S. leadership in quantum.
Disclosure: Zachary Yerushalmi is an indirect shareholder of IonQ.



